Medical breakthrough offers hope to people with same stiff person syndrome as Céline Dion
Doctors have made a potentially significant breakthrough in treating stiff person syndrome, the autoimmune condition affecting singer Céline Dion, with CAR-T cell therapy showing dramatic improvements in patients.
Stiff person syndrome (SPS) is a rare autoimmune disease attacking the central nervous system, causing severe body rigidity and painful muscle spasms. Despite decades of research, no cure existed until now.
The novel treatment, CAR-T cell therapy, reprograms a patient's immune cells to fight disease. During the study, SPS patients' T cells were extracted and engineered to eliminate disease-causing cells.
Dramatic Improvements
Patients who previously needed help with daily tasks and struggled to walk have regained their ability to participate in everyday life. Some have returned to work and resumed hobbies they thought they'd lost forever.
What was most striking was the degree of improvement we saw in some patients. With existing treatments, we may be able to improve symptoms, but we very rarely see patients return to their previous level of function.
Patient Testimonials
Jonathan Walden, who previously needed help walking and with basic tasks, has returned to work after treatment. 'I can go to work every single day. I can do everything I did before. I go hunting; I can go fishing,' he said.
Shari St Germain experienced major improvements after suffering severe leg cramps and falls. 'After the treatment, I got up one day and I'm like 'I'm feeling really good', and I went to walk on the treadmill,' she recalled.
Broader Implications
Dr Sean Pittock emphasized that CAR-T therapy has already transformed cancer treatment and shows potential for autoimmune neurological diseases. 'The results in stiff person syndrome offer tremendous hope,' he stated.
Céline Dion announced her SPS diagnosis in December 2022, revealing the condition affected 'every aspect of my daily life', including her voice. The research provides new hope for patients like her.
Yasmin Sheikh of Anthony Nolan called the research 'an exciting development' that could extend CAR-T therapies beyond blood cancer. The next step is determining whether improvements will be sustained over time.
Related
